– Appoints Carolyn Bertozzi, Ph.D., Nobel
Laureate and Leading Voice for Chemical Biology, Emerging
Technology, and Life Sciences Companies –
– Michael W. Bonney Steps Down as Executive
Chair and Continues on Board as Non-Independent Director –
– Amy W. Schulman will Assume Role of Chair of
the Board –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi
therapeutics company, today announces appointment of Carolyn
Bertozzi, Ph.D. a Nobel Laureate to the Board. Dr. Bertozzi is
known is known for her work in chemical biology. She is a pioneer
for emerging technology and has founded ten biopharmaceutical
companies and guided more than a dozen academic and professional
organizations and life sciences companies in leadership and board
positions.
Alnylam also announced today that Board member and Lead
Independent Director Amy W. Schulman, will assume the role of Chair
of the Board from Michael W. Bonney, who will continue on the Board
as a non-independent director. Mr. Bonney will be stepping down
from his interim role as Executive Chair where he was focused on
integrating the ethics and compliance function at Alnylam, a role
he assumed for just over a year during which the company appointed
a new Chief Ethics and Compliance Officer.
“We are thrilled to have Dr. Bertozzi’s perspectives on the
Board as Alnylam nears key milestones in our P5x25 strategy. Dr.
Bertozzi’s technical and leadership expertise will help Alnylam in
our goal to serve more patients than ever before,” said Yvonne
Greenstreet, MBChB, Chief Executive Officer of Alnylam. “We would
like to thank Mr. Bonney for his contributions as Executive Chair
while overseeing the continued strengthening of our compliance
function at Alnylam. We look forward to continued contributions
from both Mr. Bonney as non-independent Director and Ms. Schulman
in her new Chair role.”
“I am honored to support Alnylam’s ambitions to build a top-tier
biopharmaceutical company based on the tremendous potential of RNAi
therapeutics,” said Carolyn Bertozzi, Ph.D. “Alnylam has gained
momentum launching new therapies and maximizing its pipeline based
on proven technology, and I am looking forward to working with this
esteemed team to help more people in need.”
Dr. Bertozzi is well-regarded as the founder of the
bioorthogonal chemistry field and has co-founded multiple
biopharmaceutical companies including Palleon Pharmaceuticals,
InterVenn Bio, Grace Science and Lycia Therapeutics. Dr. Bertozzi
currently serves on the scientific advisory boards of Rayze Bio,
Spotlight Therapeutics, and Ambigon Therapeutics, among others. Dr.
Bertozzi also serves as the Baker Family Director of Stanford
University’s Sarafan ChEM-H Institute, and as the Anne T. and
Robert M. Bass Professor of Chemistry in the Stanford School of
Humanities and Sciences. She is an investigator at the Howard
Hughes Medical Institute, and a member of several venerable
organizations, including the National Academy of Sciences, National
Academy of Medicine and National Academy of Inventors, as well as
the Royal Society (UK), Accademia Nazionale dei Lincei and the
German Academy of Sciences Leopoldina.
Dr. Bertozzi has been recognized with many distinctions,
including a MacArthur Fellowship, the Lemelson-MIT Prize, the Welch
Award in Chemistry, the Heineken Prize for Biochemistry and
Biophysics, and the Wolf Prize in Chemistry. She has also been the
Editor-in-Chief of ACS Central Science since 2014.
Mr. Bonney was appointed as Executive Chair of Alnylam in August
2021, having been elected to Alnylam’s Board of Directors in 2014.
His experience leading the development and growth of successful,
commercial-stage biopharmaceutical companies has helped Alnylam
during a time of significant growth, and as the company sought to
further strengthen its ethics and compliance function and
integration with the business. During Mr. Bonney’s tenure in this
role, he oversaw the appointment of Piyush Sharma, JD, as Alnylam’s
new Chief Ethics and Compliance Officer.
Ms. Schulman was elected to the Alnylam Board of Directors in
2014. She is currently Managing Partner, Polaris Partners;
Co-founder, Executive Chair, and former Chief Executive Officer of
Lyndra Therapeutics; member of the Board of Directors of SQZ
Biotech; and Senior Lecturer at Harvard Business School. Ms.
Schulman sits on the board of Mount Sinai Hospital in New York.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation
of RNA interference (RNAi) into a whole new class of innovative
medicines with the potential to transform the lives of people
afflicted with rare and prevalent diseases with unmet need. Based
on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach yielding transformative
medicines. Since its founding 20 years ago, Alnylam has led the
RNAi Revolution and continues to deliver on a bold vision to turn
scientific possibility into reality. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), GIVLAARI®
(givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and
Leqvio® (inclisiran), which is being developed and commercialized
by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of
investigational medicines, including multiple product candidates
that are in late-stage development. Alnylam is executing on its
“Alnylam P5x25” strategy to deliver transformative medicines in
both rare and common diseases benefiting patients around the world
through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on Twitter at @Alnylam, on LinkedIn, or on
Instagram.
Alnylam Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. All statements
other than historical statements of fact regarding Alnylam’s
expectations, beliefs, goals, plans or prospects including, without
limitation expectations regarding, Alnylam’s aspiration to become a
leading biotech company and the planned achievement of its “Alnylam
P5x25” strategy, the potential for Alnylam to identify new
potential drug development candidates and advance its research and
development programs, Alnylam’s ability to obtain approval for new
commercial products or additional indications for its existing
products, and Alnylam’s projected commercial and financial
performance should be considered forward-looking statements. Actual
results and future plans may differ materially from those indicated
by these forward-looking statements as a result of various
important risks, uncertainties and other factors, including,
without limitation: the direct or indirect impact of the COVID-19
global pandemic or any future pandemic on Alnylam’s business,
results of operations and financial condition and the effectiveness
or timeliness of Alnylam’s efforts to mitigate the impact of the
pandemic; the potential impact of the January 2022 leadership
transition on Alnylam’s ability to attract and retain talent and to
successfully execute on its “Alnylam P5x25” strategy; Alnylam's
ability to discover and develop novel drug candidates and delivery
approaches, including using Alnylam’s IKARIA and GEMINI platforms,
and successfully demonstrate the efficacy and safety of its product
candidates; the pre-clinical and clinical results for its product
candidates, including ALN-APP, patisiran and vutrisiran; actions or
advice of regulatory agencies and Alnylam’s ability to obtain and
maintain regulatory approval for its product candidates, including
patisiran and vutrisiran, as well as favorable pricing and
reimbursement; successfully launching, marketing and selling its
approved products globally; delays, interruptions or failures in
the manufacture and supply of its product candidates or its
marketed products; obtaining, maintaining and protecting
intellectual property; Alnylam’s ability to successfully expand the
indication for ONPATTRO or AMVUTTRA in the future; Alnylam's
ability to manage its growth and operating expenses through
disciplined investment in operations and its ability to achieve a
self-sustainable financial profile in the future without the need
for future equity financing; Alnylam’s ability to maintain
strategic business collaborations; Alnylam's dependence on third
parties for the development and commercialization of certain
products, including Novartis, Sanofi, Regeneron and Vir; the
outcome of litigation; the potential impact of a current government
investigation and the risk of future government investigations; and
unexpected expenditures; as well as those risks more fully
discussed in the “Risk Factors” filed with Alnylam's most recent
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) and in its other SEC filings. In
addition, any forward-looking statements represent Alnylam's views
only as of today and should not be relied upon as representing its
views as of any subsequent date. Alnylam explicitly disclaims any
obligation, except to the extent required by law, to update any
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230105005805/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom (Investors and Media)
+1-617-682-4340
Josh Brodsky (Investors) +1-617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024